Sanofi-Synthélabo is engaged in the development and manufacture of prescription pharmaceuticals in four main therapeutic categories: Cardiovascular/Thrombosis, Central Nervous System, Internal Medicine and Oncology. Certain of the Company's products are sold both by the Company and, in selected markets, by its alliance partners and licensees, giving these products a broad, worldwide market presence. The Company's Cardiovascular/Thrombosis products include Aprovel, Tildiem, Cordarone, Ticlid, Plavix and Fraxiparine. Central Nervous System products include Stilnox, Depakine, Dogmatil and Solian. The Company's leading Internal Medicine offering is Xatral. Its first product in the area of Oncology is Eloxatine.